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Abstract: The surface of foils and vascular grafts made from a thermoplastic polycarbonate
urethanes (PCU) (Chronoflex AR) were chemically modified using gas plasma treatment, binding
of hydrogels—(1) polyethylene glycol bisdiamine and carboxymethyl dextran (PEG-DEX) and
(2) polyethyleneimine (PEI)—and immobilization of human antithrombin III (AT). Their biological
impact was tested in vitro under static and dynamic conditions. Static test methods showed
a significantly reduced adhesion of endothelial cells, platelets, and bacteria, compared to untreated
PCU. Modified PCU grafts were circulated in a Chandler-Loop model for 90 min at 37 ◦C with human
blood. Before and after circulation, parameters of the hemostatic system (coagulation, platelets,
complement, and leukocyte activation) were analyzed. PEI-AT significantly inhibited the activation
of both coagulation and platelets and prevented the activation of leukocytes and complement.
In conclusion, both modifications significantly reduce coagulation activation, but only PEI-AT creates
anti-bacterial and anti-thrombogenic functionality.
Keywords: polycarbonate urethane; thromboresistance; antithrombin III; anti-bacterial;
hemocomaptibility
1. Introduction
Polycarbonate urethanes (PCUs) have been used in implantable medical devices because of their
superior biocompatibility, attractive mechanical properties, and improved oxidative biostability [1–5].
However, thrombus formation may still occur when artificial organs and biomedical devices
made of PCU are in contact with blood for extended periods of time [6–8]. Currently this
is managed by anti-platelet therapy, however, this presents a risk of bleeding [8]. Therefore,
there remains a pressing need for non-thrombogenic surface coatings that can reduce this reliance
on pharmacological intervention. Approved surface coatings include the immobilization of drugs
that block fibrin formation and prevent platelet adhesion/activation. Promising coating strategies
for blood contacting medical devices are the immobilization of heparin [9–11], thrombomodulin [12],
phosphatidylcholine [13], and argatroban [14,15].
The present study pursued the strategy to immobilize antithrombin III (AT) on the surface
of a plasma-treated thermoplastic PCU (Chronoflex AR) that was linked by polyethylene glycol
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bisdiamine (PEG), carboxymethylied dextran (DEX), and polyethylenimine (PEI)-based hydrogels.
AT is a serine protease inhibitor that inactivates proteases from the contact activation pathway, mainly
activated factor II (IIa, thrombin). However, contact of blood with polymeric surfaces can result in
a decrease in the AT activity as shown during cardiopulmonary bypass operation [16] or after the
implantation of mechanical support devices such as ventricular assist devices [17]. The reduction in
AT activity can be responsible for subclinical coagulation, heparin resistance, and clinically relevant
thromboembolic events [6]. The application of recombinant AT may be one method of avoiding
these complications in heparin-resistant patients that require cardiopulmonary bypass operation [18].
Furthermore, Sask and coworkers immobilized an AT-heparin anticoagulant complex on the surface of
a segmented polyurethane and demonstrated improved anticoagulant properties for this surface via
direct thrombin inhibition by the AT portion of the complex [19].
In this work, human AT was used to modify the surface of a commercially available PCU
linked with different hydrogels (PEG-DEX and PEI). In a previous study we showed that covalent
binding of AT improved anti-thrombotic properties of untreated PCU, independent of the type of
connecting hydrogel [20]. However, reproducible low platelet adhesion was only documented for
the combination of PEG-DEX and PEI with AT [20]. Therefore, these modifications were analyzed
to verify their antithrombotic functionality under physiological conditions, such as shear stress.
The hemocompatibility of the two surface modifications was tested according to ISO 10993-4 using
a Chandler-Loop model in order to exclude hemostatic activation induced by the surface chemistry [21].
2. Methods
2.1. Production of PCU Foils and Spiral PCU Grafts
The aromatic PCU ChronoFlex AR (CF, AdvanSource Biomaterials, Wilmington, MA, USA) was
processed according to the manufacturer’s instructions [1].
Processing of foils: Dissolved CF (12 mL) was poured into a flat mold (155 mm × 25 mm × 5 mm)
and dried in a vented air oven (Carbolite, Neuhausen, Germany) (45 ◦C, 12 h). The foil (thickness,
0.5 mm) was incubated in a heated vacuum chamber (Binder, Tuttlingen, Germany) (1.5 mbar, 75 ◦C,
3 days). Round (diameter, 6 mm) or rectangular samples (12 mm × 3.5 mm) were prepared.
Processing of spiral PCU grafts: A helically wound, round stock made of aluminum (diameter,
5 mm; length, 600 mm) was mounted onto a robot (Kuka, Augsburg, Germany). The stock was dipped
into dissolved CF, and the robot panned the stock (around its helical and horizontal axis) in a climate
chamber (custom creation; relative humidity ≤30%; 28 ◦C). The dipping process was repeated three
times to obtain a wall thickness of 0.5 mm. After having dried in the climate chamber, the helical
graft was placed into the vented air oven (45 ◦C, 12 h), incubated in the heated vacuum chamber, and
immersed in ethanol (≥99.5%, p.a., Carl Roth, Karlsruhe, Germany) (room temperature, RT; 6 h) to
facilitate the removal of the graft from the stock.
2.2. Surface Modifications
The details on handling and modifying the PCU discs and helical grafts have been described
previously [20]. Chemicals were obtained from Merck (Darmstadt, Germany) or Sigma-Aldrich
(Munich, Germany), unless noted otherwise.
Material was cleaned briefly in ethanol, dried, and activated by modified N2 plasma treatment
with an additional supply of carbon dioxide. Plasma-activated PCU (pPCU) was incubated
in 0.9% sodium chloride solution (NaCl) (50 ◦C, 2 h), and incubated in aqueous NHS/EDC
(N-hydroxysuccinimide/1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) (0.1 M/0.1 M) (RT, 20 min)
(activated PCU samples).
PEG-DEX-AT modification: Activated PCU samples were incubated in 0.1 M carbonate buffer
pH 8.4/0.6 M potassium sulfate with 1 mg/mL polyethylene glycol bisamine (PEG-diamine;
Sigma-Aldrich) (50 ◦C, 2 h) [22] (PEG). After having been cleaned with deionized water, carboxymethyl
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dextran (DEX) was immobilized at the activated sample surfaces (PEG-DEX). To accomplish
immobilization, DEX synthesized by the reaction of dextran (Sigma-Aldrich) with bromoacetic acid [23]
was incubated in aqueous EDC/NHS (0.2 M/0.1 M) for 20 min. PEG samples were coupled with
1 mg/mL of activated DEX in carbonate buffer environment (2 h, RT) (PEG-DEX). Having been rinsed
in water, PEG-DEX was treated with aqueous EDC/NHS (0.1 M/0.1 M) and incubated overnight with
1 IU/mL of human antithrombin III (AT; Kybernin® P, CLS Behring, Marburg, Germany) at 4 ◦C.
PEI-AT modification: pPCU samples were incubated with 3 mg/mL branched polyethyleneimine
(PEI, Sigma-Aldirch) (2 h, RT) (PEI). AT was preactivated in aqueous EDC/NHS (0.2 M/0.1 M) (20 min,
RT). Subsequently, preactivated AT (1 IU/mL) was incubated with PEI samples (19 h, 4 ◦C) (PEI-AT).
All modified samples were washed with deionized water, dried, and stored at 4 ◦C.
Untreated and modified PCU samples were blinded by the allocation of numbers.
2.3. Elasticity and Wettability of Surface Modifications
The focus of the present study is the analysis of the biological effect of surface modifications.
Therefore, only a few methods were performed to describe surface characteristics: the maintenance
of elasticity (Dynamical Mechanical Analysis, DMA) and an examination of the wettability. Fourier
transform infrared (FTIR) and nuclear magnetic resonance (NMR) spectroscopy were not performed.
DMA was used to analyze the temperature-dependent visco-elastic properties and to determine
the complex modulus (E′, modulus of elasticity; E′ ′, damping values; tan d = E′ ′/E′) using
Netzsch-DMA 242 C (Netzsch-Gerätebau, Selb, Germany). After applying sinusoidal stress (7 N,
1 Hz) to the sample, we measured the strain in the material while changing the temperature (−100 ◦C
to 100 ◦C; heating rate, 2 K/min). In this way, we determined the change in the glass transition
temperature of the rectangular foil materials that was caused by surface modification.
Wettability was evaluated by means of water contact angles using the sessile drop. A drop of
deionized water (2 µL) was put onto the sample surface. We photographed the drops after exactly 10 s
and measured the contact angle values [24]. Each sample was measured five times, and the results
were averaged.
2.4. Bacterial Adhesion
Bacterial adhesion assay: Bacterial adhesion was initiated with gram-positive Staphylococcus
epidermidis. S. epidermidis is a common human commensal microorganism that colonizes skin and
mucosal surfaces; it has become an opportunistic pathogen, due to its ability to colonize invasive
medical devices causing blood stream infections [25]. Only untreated, PEG-DEX-AT and PEI-AT
samples were analyzed. Untreated and modified PCU discs were inserted into 96-well polypropylene
microplates (Nunc, Thermo Fisher, Waltham, MA, USA) and incubated in a suspension of bacteria
(100 µL; 12 × 105 colony forming unit, CFU mL−1) in BM medium (tryptone, 10 g/L; yeast extract,
5 g/L; NaCl, 5 g/L; K2HPO4, 1 g/L; glucose, 1 g/L) (37 ◦C, 30 min). The samples were carefully rinsed
in sterile isotonic phosphate buffer saline (PBS) under continuous shaking at 100 rpm. The remaining
solution was blown off with sterile, compressed air. The surface of the discs was placed on blood
agar plates (37 ◦C, 19 h). Colony-forming bacteria produced recesses in the agar surface that were
counted per surface area of the disc. The ratio of bacteria adherent to modified PCU discs compared to
untreated PCU samples was analyzed.
Bacterial proliferation assay: Untreated and modified PCU discs were incubated with
S. epidermidis for 8 h and 120 h, gently washed, fixed with pure methanol, stained with crystal
violet (0.2% aqueous solution; 15 min), and rinsed with PBS. We extracted the crystal violet that was
bound to the bacteria with 200 µL ethanol and determined optical density at 595 nm.
2.5. Platelet Adhesion—Hemocompatibility
In a previous study, a static platelet adhesion test was used to discriminate the platelet adhesion
of different surface modifications, including all intermediate modified PCU materials [20]. In brief,
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plasma-activation did not improve hemocompatibility. The crucial step was the binding of PEG to
significantly reduce platelet adhesion. Subsequent binding of DEX and AT showed no additional
improvement. In contrast, the binding of PEI alone did not affect platelet adhesion. The additional
coupling of AT induced a significant increase in thromboresistance of PCU. The same test was used to
emphasize the extent of platelet adhesion on PEG-DEX-ATT and PEI-ATT modified PCU samples using
scanning electron microscopy (SEM). Human citrated venous blood was drawn from healthy male
volunteers who had given their written consent, as per institutional ethics guidelines (No. 10-101-0159).
Platelet-rich plasma (PRP) was isolated as described earlier [20]. For platelet adhesion testing, PRP
(50 µL; 5 × 107 platelets per 0.3 cm2) was coincubated with the PCU samples (37 ◦C, 5% CO2, 30 min),
washed with PBS and processed as described in Section 2.7.
2.6. Chandler-Loop Experiments
In vitro experiments were conducted with a dynamic rotation model (modified
Chandler-Loop) [26]. The experiments were done in the laboratory of the Department of
Throacic and Cardiovascular Surgery at University Hospital Tuebingen. Each spiral PCU graft
(untreated and treated) was filled with 12 mL of donor blood. The loops were vertically rotated
(37 ◦C, 90 min). Blood was collected for cell counting and measurement of complement (SC5b-9),
thrombin-antithrombin-complex (TAT), polymorphonuclear (PMN)-elastases, and ß-thromboglobulin
(TG) levels. Blood without any contact to material was used as negative control. Changes in
markers of coagulation, complement activation, and blood cell release factors were measured
using commercially available enzyme-linked immunosorbent assay (ELISA) kits (TG (Asserachrom
ß-TG, Diagnostica Stago, Asnieres, France); TAT (Enzygnost TAT micro, Dade Behring, Schwalbach,
Germany); PMN-elastase (Demeditec, Diagnotics, Kiel, Germany); SC5b-9 (Quidel, San Diego, CA,
USA)). Blood cells were counted in EDTA blood using a fully automated cell counter system (micros
60 ABX Hematology, Montpellier, France).
2.7. Scanning Electron Microscopy (SEM)
Thrombogenicity of the modified spiral grafts and flat discs was verified with SEM. After the
end of the experiments, the samples were rinsed with PBS and incubated in 2% glutaraldehyde.
After extensive rinsing with PBS, the remaining water was then removed from the grafts using
40%–100% ethanol in ascending concentrations. Finally, all samples underwent critical point drying,
were sputtered with gold palladium, and were subsequently analyzed with SEM (EVO-LS10, Zeiss,
Oberkochen, Germany).
2.8. Statistics
Data are presented as median (IQR, interquartile range) and were analyzed with the Wilcoxon
Signed Rank Test (Sigma-Stat, SPSS, Chicago, IL, USA) after having passed the Friedman Test
(Sigma-Stat, SPSS). p values of ≤0.05 were considered significant.
3. Results
3.1. Mechanical Properties
The dynamic mechanical relaxation behavior of the rectangular untreated and modified PCU
samples is shown in Figure 1. The glass transition of the analyzed samples was identified by the
respective drops in the storage modulus (E′) and prominent peaks in tan d and loss modulus (E′ ′).
The glass transition temperature of the untreated PCU sample was higher than that of any modified
PCU sample (untreated, −24 ◦C; PUR-DEX-A, −44 ◦C; PEI-AT, −42 ◦C). This difference in glass
transition temperatures was attributed to a greater flexibility of the modified PCU samples than that
of the untreated PCU samples. The different surface modifications did not differ with regard to
their elastic properties. At 37 ◦C, the measured values were within the same range, which indicated
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the absence of a significant difference in the material properties between untreated and modified
samples (representative data for E’ (Pa): untreated, 9.82; PUR-DEX-A, 9.59; PEI-AT, 8.77; data for tan d:
untreated, 0.094; PUR-DEX-A, 0.093; PEI-AT, 0.083).Materials 2017, 10, 335  5 of 12 
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contact with all modified PCU samples. Only untreated PCU samples showed a significant increase 
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Figure 1. Mechanical properties of untreated and modified polycarbonate urethanes (PCU) samples.
DMA curves of (A) elastic modulus (E′) and (B) tan d; (C) loss modulus curves (E′ ′) versus temperature
for untreated and modified PCU samples.
3.2. Wettability
The contact angles of water on AT-modified PCU discs (PEG-DEX-AT, 62◦ ± 3◦; PEI-AT,
58◦ ± 2.6◦) were significantly reduced compared to untreated PCU samples (78◦ ± 1.7◦; p < 0.001
vs. each modification). There was no difference in the contact angles of the AT-modified samples
(p = 0.081).
3.3. Biofilm Formation on Modified PCU
Bacterial adhesion an proliferation on the s rface of biom terial is essential or biofilm formation.
The amount of adhering S. epidermidis was highest on untreated PCU samples. As shown in Figure 2A,
CFUs were significantly reduced on PEG-DEX-AT (8% ± 4%) and PEI-AT (23% ± 13%), compared
to untreated PCU (each, p ≤ 0.001). In addition, bacterial proliferation was inhibited after contact
with all modified PCU samples. Only untreated PCU samples showed a significant increase in biofilm
formation after 5 days (p = 0.013; Figure 2B).
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Figure 2. Bacterial adhesion and biofilm formation of untreated and modified PCU samples. Each
modification significantly reduced bacterial adhesion (n = 12) (A); and biofilm formation (n = 3) (B);
compared to untreated PCU (§, p ≤ 0.05; §§§, p ≤ 0.001). CFU, colony forming unit. Data are presented
as median with 25/75 and 5/95 percentile (error bars).
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3.4. Hemocompatibility under Static Culture Conditions
The surface of untreated PCU samples was densely covered with fibrin networks and activated
platelets (Figure 3A). The activated platelets showed spread platelets with long pseudopodia.
In contrast, few platelet deposits were found on PEG-DEX-AT- and PEI-AT-modified surfaces
(Figure 3B,C). Single platelets with few and short pseudopodia were visible.
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Figure 3. Hemocompati using a s atic platelet adhesion assay. Repres nt tive samples of
(A) untreated PCU; (B) olyethylene glycol bisdiamine–carboxymethyl dextra –antithrombin III
(PEG-DEX-AT); and (C) polyethylenei ine (PEI)-AT modified PCU. The samples were incubated
with platelet-rich plasma. Adherent platelets were visualized with scanning electron microscopy
(SEM). Inserts present higher magnification. The test was replicated with 5 platelet donors
(independent experiments).
3.5. Chandler-Loop Experiments
No material showed any sign of clot formation after 90 min recirculation in the Chandler-Loop
model. SEM showed more platelet sticking and adherence of blood cell on the surface of untreated
PCU samples (Figure 4).
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The TAT level of untreated PCU was 3.4 times higher than that of PEG-DEX-AT (2.1/11.1) (p = 0.012), 
and 3.7 times higher than that of PEI-AT (3.2/23.4) (p = 0.002). Levels of the complement factor 
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PCU and PEI-AT had no significant effect on complement activation. Platelet hyperactivity was 
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Figure 4. Platelet adhesion after recirculation of heparinized blood in grafts made of (A) untreated
PCU; (B) PEG-DEX-AT; and (C) PEI-AT in the Chandler-Loop model. White arrow indicates adherent
platelets in representative images of scanning electron microscopy (SEM). The test was replicated with
5 blood donors (independent experiments).
TAT was measured to detect coagulation activation (Figure 5A). Contact of blood with untreated
PCU resulted in a significant increase in TAT levels (p ≤ 0.001, compared to control blood). The TAT
level of untreated PCU was 3.4 times higher than that of PEG-DEX-AT (2.1/11.1) (p = 0.012), and 3.7
times higher than that of PEI-AT (3.2/23.4) (p = 0.002). Levels of the complement factor SC5b-9
significantly increased in the presence of PEG-DEX-AT (p ≤ 0.001) (Figure 5B). Untreated PCU and
Materials 2017, 10, 335 8 of 12
PEI-AT had no significant effect on complement activation. Platelet hyperactivity was measured
by the release of ß-TG (Figure 5C). Untreated PCU and PEG-DEX-AT caused a significant release
of ß-TG (p ≤ 0.001; p ≤ 0.001 compared to negative control), but PEI-AT did not induce platelet
activation (p = 0.346). The protective effect of PEI-AT was 2.4 times lower than that of untreated PCU
(1.3/6.9) (p≤ 0.001). These data correlated with the number of platelets (Figure 5D). Blood contact with
untreated PCU and PEG-DEX-AT significantly decreased platelet counts (p = 0.007; p = 0.003 compared
to negative control). No change in platelet count was observed for PEI-AT (p = 0.316). There was no
difference between the samples. Granulocyte activation was measured by means of the release of
PMN-elastase (Figure 5E). Inflammatory response was highest for PEG-DEX-AT (p ≤ 0.001). Untreated
PCU and PEI-AT had no significant effect on leukocyte activation.
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Figure 5. Effect of untreated and modified PCU samples on blood responses using a Chandler-Loop
model. Specific parameters were detected after 90 min (A) Thrombin-antithrombin III complex
(TAT); (B) SC5b-9; (C) ß-thromboglobulin (ß-TG); (D) platelet count; and (E) PMN-elastase (PMN,
polymorphonuclear). Data from 5 independent runs are presented as median with 25/75 and 5/95
percentile (error bars). Statisitcs: *, significant alteration compared to control (*, p ≤ 0.05; **, p ≤ 0.05;
***, p ≤ 0.001); $, significant difference compared to untreated PCU samples ($, p ≤ 0.05; $$, p ≤ 0.05;
$$$, p ≤ 0.001).
4. Discussion
Chemical modifications have been used to improve the hemocompatibility of Chronoflex AR as a
potential material for the pump chamber of implantable VAD systems [20]. Among the modified PCU
samples used in the present study, PEI-AT modification had minor effects on mechanical properties
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and showed increased wettability, reduced bacterial cell binding, suppressed platelet adhesion and
activation, and activation of complement and coagulation under shear stress.
Plasma treatment and chemical modification alter the physical and thermal properties of
Chronoflex AR. Each modification employed in our study decreased the glass transition temperature
of PCU, which was attributed to a greater flexibility of the modified PCU discs [27,28]. The two
modifications did not differ with regard to their elastic properties.
Each surface modification significantly reduced the adhesion and proliferation of S. epidermidis
to untreated PCU samples. The introduction of PEG or PEI-based hydrogels may be responsible for
preventing bacterial adhesion [29,30]. Park et al. [29] used different PEG modifications on polyurethane
surfaces and showed a significant reduction in S. epidermidis adhesion on sulfonated PEG, long-chain
PEG, and heparinized PEG surfaces. Such coatings show antifouling properties and significantly reduce
protein adsorption and bacterial adhesion because of the high entropy and strong affinity of PEG for
water [31]. Furthermore, coating glass or polyethylene slides with hydrophobic N-alkyl-PEI polycations
kills gram-positive human pathogen Staphylococcus aureus and gram-negative Escherichia coli [32].
These surface modifications may be useful to reduce bacterial colonization on medical devices. Clinical
data have reflected the necessity of such antimicrobial surface coatings. Rosenfeldt et al. [33] showed
in a single center study that 45% of patients with a VAD developed VAD-associated bacteremia with
an incidence of 5.6 episodes per 1000 support days.
The AT-modified samples in the current study resisted platelet adhesion and activation, which
was impressively shown by SEM. Under static conditions, activated platelets accumulate on untreated
PCU surfaces and produce extensive fiber networks. The inadequate hemocompatibility of untreated
polyurethanes was approved by other studies [2,14,34], limiting its use in blood-contacting applications.
We supposed that the hydrophobic character of untreated PCU caused a higher adhesion of platelets.
The immobilization of PEG-DEX-AT and PEI-AT modifications reduced hydrophobicity of the surface,
prevented platelet adhesion and suppressed the outspread and pseudopodium deformation of the
adherent platelet, which indicates improved blood compatibility. In a previous study, our group
demonstrated that the binding of PEG-DEX and PEI hydrogels to plasma-activated PCU significantly
reduced platelet adhesion under static conditions [20]. This was confirmed by Coll Ferrer et al. [35].
The additional immobilization of AT did not improve the thromboresistance of the material [20].
However, it could not be excluded that the immobilized AT performed its physiological function.
Similar results were shown by Ito et al. [36], who synthesized an acrylamide derivative of a thrombin
inhibitor and polymerized it to the surfaces of polymer membranes. This construct deactivated
thrombin and suppressed the adhesion of platelets. Furthermore, surface coating with argatroban,
a direct thrombin inhibitor, reduced thrombus formation in an extracorporeal circulation circuit [15].
Finally, the Chandler-Loop model was used in consideration of the fact that blood-contacting
devices not only interact with blood in direct proximity but also with the entire circulating blood
volume [37,38]. The Chandler-Loop model simulates arterial flow conditions [39,40] and enables
the testing of hemocompatibility of artificial materials according to ISO 10993-4 standard tests [41].
The limited hemocompatibility of polyurethane was shown by the activation of the coagulation
cascade exemplified by an increase in TAT and ß-TG levels and a decrease in platelet count,
whereas the complement and inflammatory systems were only slightly influenced. Alterations in
the hemostatic response were inhibited in contact of PCU with immobilized AT. However, only the
PEI-AT modification significantly reduced coagulation (TAT) and platelet activation (ß-TG) without
altering the complement and granulocyte reaction. PEG-DEX-AT modification only reduced the levels
of TAT; platelet activation remained high, complement and inflammatory systems were stimulated,
and platelets adhered to the inner surfaces of the modified tubular grafts.
With the Chandler-Loop model, we were able to compare more than two different PCU surface
modifications in one experimental setting, which is a major limitation of other in vitro as well as
in vivo models. Nevertheless, one limitation of our study was the limited surface characterization of
the modified PCU discs (FTIR, NMR) and missing data from intermediate modified PCU samples.
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More details have already been published [20]. Furthermore, mechanistic studies on the functionality
of AT failed. However, the present study was focused on the biological responses of different surface
modifications to human blood cells under shear stress. Further studies will be necessary for additional
characterization, particularly of the surface properties.
5. Conclusions
While both PEG-DEX-AT and PEI-AT significantly reduce coagulation activation, only PEI-AT
creates anti-bacterial and anti-thrombogenic functionality. Future studies will show whether this
modification is suitable for cardiovascular tissue engineering.
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